We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+4.23%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.4B
AUM Growth
+$2.4B
Cap. Flow
+$169M
Cap. Flow %
7.05%
Top 10 Hldgs %
44.25%
Holding
367
New
126
Increased
77
Reduced
66
Closed
85

Top Buys

Rank Stock Value
1
TPST icon
Tempest Therapeutics
TPST
+$94.4M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$24M
3
AGN
Allergan plc
AGN
+$13.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$11.9M
5
MBLY
Mobileye N.V.
MBLY
+$8.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$42.1M
2
GILD icon
Gilead Sciences
GILD
+$11.5M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$11.1M
4
A icon
Agilent Technologies
A
+$6.68M
5
ADVM
Adverum Biotechnologies
ADVM
+$3.71M

Sector Composition

Rank Sector Weight
1 Healthcare 9.36%
2 Technology 0.55%
3 Energy 0.39%
4 Industrials 0.16%
5 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXMD icon
226
TherapeuticsMD
TXMD
$23.8M
$504K 0.02%
1,665
-9,332
-85% -$2.28M
ARWR icon
227
Arrowhead Research
ARWR
$12.1B
$502K 0.02%
+74,204
New +$527K
NBSE
228
PUT
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$498K 0.02%
+5
New +$16.5K
NBSE
229
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$496K 0.02%
488
+363
+290% +$1.2M
PLUR icon
230
Pluri
PLUR
$18.1M
$490K 0.02%
+2,188
New +$514K
RVNC
231
DELISTED
Revance Therapeutics, Inc.
RVNC
$478K 0.02%
23,065
-53,335
-70% -$921K
ESPR
232
DELISTED
Esperion Therapeutics
ESPR
$463K 0.02%
+5,000
New +$323K
ACGN
233
DELISTED
Aceragen Inc
ACGN
$438K 0.02%
+869
New +$530K
INFI
234
PUT
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$419K 0.02%
300
-1,507
-83% -$23K
CERS icon
235
Cerus
CERS
$585M
$417K 0.02%
+100,000
New +$512K
IONS icon
236
PUT
Ionis Pharmaceuticals
IONS
$9.14B
$414K 0.02%
+65
New +$4.41K
IPCI
237
PUT
DELISTED
Intellipharmaceuticals International Inc.
IPCI
$413K 0.02%
142
+15
+12% +$364
PGEN icon
238
PUT
Precigen
PGEN
$1.97B
$408K 0.02%
94
-939
-91% -$33.7K
BDSI
239
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$392K 0.02%
+37,300
New +$510K
NSPH
240
DELISTED
NANOSPHERE INC. COM NEW
NSPH
$383K 0.02%
82,617
-28,637
-26% -$164K
SNOA icon
241
Sonoma Pharmaceuticals
SNOA
$5.46M
$352K 0.01%
+465
New +$395K
ADVM
242
CALL
DELISTED
Adverum Biotechnologies
ADVM
$328K 0.01%
+8
New +$3.38K
BCRX icon
243
PUT
BioCryst Pharmaceuticals
BCRX
$2.48B
$323K 0.01%
+358
New +$3.71K
AGIO icon
244
Agios Pharmaceuticals
AGIO
$2.14B
$298K 0.01%
+3,163
New +$354K
ACHC icon
245
Acadia Healthcare
ACHC
$3.01B
$296K 0.01%
+9,074
New +$582K
GEVA
246
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$294K 0.01%
+3,013
New +$319K
KERX
247
PUT
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$293K 0.01%
230
+102
+80% +$1.31K
SRPT icon
248
Sarepta Therapeutics
SRPT
$1.63B
$291K 0.01%
21,943
-83,057
-79% -$1.11M
HALO icon
249
PUT
Halozyme
HALO
$9.9B
$288K 0.01%
+202
New +$2.91K
OCGN icon
250
Ocugen
OCGN
$420M
$275K 0.01%
458
-381
-45% -$220K
8 9
10
11 12

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2015 Portfolio in Review

As of Q1 2015, Sabby Management held 367 positions worth $2.4B, up 75,773% from $3.17M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management deployed $169M of net new capital in Q1 2015, opening 126 new positions and adding to 77 existing holdings. Its largest new stake was Tempest Therapeutics: 709 shares worth $4.69M.

By sector, the portfolio is most concentrated in Healthcare at 9.4% of assets, up from 9.2% a quarter earlier, followed by Technology and Energy.

On the sell side, the largest reduction was Achillion Pharmaceuticals, an estimated $11.1M trimmed.

  • Sabby Management's largest Q1 2015 buy was Tempest Therapeutics: 709 shares worth $4.69M.
  • Sabby Management added most to Allergan plc in Q1 2015, an estimated $13.8M increase.
  • Sabby Management's biggest Q1 2015 reduction was Achillion Pharmaceuticals, cutting an estimated $11.1M.
  • Sabby Management fully exited Pfizer in Q1 2015, selling an estimated $42.1M.
  • Sabby Management's ten largest holdings make up 44% of its $2.4B portfolio in Q1 2015.
  • Sabby Management opened 126 new positions and closed 85 in Q1 2015.
  • Sabby Management's portfolio value rose 75,773% quarter-over-quarter to $2.4B.

Based on Sabby Management's 13F filing for Q1 2015, filed 15 May 2015.